ICLUSIG® (ponatinib tablets)
- Tyrosine kinase inhibitor (TKI)
- Indicated in adult patients with
- chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation
- Philadelphia chromosome positive acute lymphoblastic leukaemia who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation
- For more product information, you may visit: https://iclusig.com.hk/
| Formulation | Package | Strength | Colour / Appearance |
|---|---|---|---|
| Tablets | 30 tablets/ bottle | 15 mg | White, biconvex, round film-coated tablets, with “A5” debossed on one side |
| 45 mg | White, biconvex, round film-coated tablets, with “AP4” debossed on one side |
Busulfex® (busulfan injection)
- Anticancer alkylating agent
- Busulfex followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in adult patients when the combination is considered the best available option
- Busulfex following fludarabine (FB) is indicated as conditioning treatment prior to haematopoietic progenitor cell transplantation (HPCT) in adult patients who are candidates for a reduced-intensity conditioning (RIC) regimen
10 mL/ vial contains busulfan 6mg/ mL
*Please refer to the full prescribing information for details